缬沙坦对CAPD患者残存肾功能的保护作用  

Protective effects of Valsartan on residual renal function in patients on CAPD

作　　者：王健[1] 肖明英 

机构地区：[1]云南省保山市第二人民医院内科,保山678000 [2]云南省保山市医院内五科,保山678000

出　　处：《中国血液净化》2005年第11期605-606,共2页Chinese Journal of Blood Purification

摘　　要：目的探讨血管紧张素Ⅱ受体拮抗剂缬沙坦是否有保护腹膜透析患者残存肾功能的作用。方法以云南省保山市第二人民医院内科34例腹膜透析患者为研究对象,随机分为治疗组和对照组,治疗组予缬沙坦40-80mg／d口服,对照组予非血管紧张素转换酶抑制剂(ACEI)和非血管紧张素受体拮抗剂(ARB)类降压药控制血压,进行随访,定期检测血压,血清肌酐,尿素氮,尿量,尿蛋白排泄率,总肌酐清除率,残存肾功能,Kt／v等指标。结果平均随访(28±13)个月,共有32例患者完成研究,与开始研究时比较,治疗组的尿量和残存肾功能下降,但无显著差异(P>0．05),而对照组则出现显著下降,(P<0．05),两组残存肾功能的下降值比较也有显著差异,(P<0．05),对照组的下降速度是治疗组的2．37倍。结论缬沙坦能有效延缓腹膜透析患者残存肾功能的丧失。Objective To explore whether the angiotensin Ⅱ receptor blocker, Valsartan has a protective effects on residual renal function in patients on CAPD. Methods Thirty-four new peritoneal dialysis patients were enrolled into this study, and were divided into two groups randomly, the subjects on study group were administered 40 to 80 mg Valsartan daily, and the controls were administered antihypertensive agents, except ACE inhibitors and/or ARBs. Patients were followed up, at each clinic visit, serum creatinine, BUN, blood pressure, urine volume, urinary protein excretion, creatinine clearance, residual renal function and Kt/v were measured. Result These patients were followed up （28±13） months, 32 patients completed the study, compared with the initial stage, the urine volume and residual renal function both were decreased, but did not reach the significant level, which on control group, these two parameters all declined significantly, （P〈0.05）： the average decline value between the two groups has significant difference, the decline of residual renal function of control group was faster than study group for 2.37 times. Conclusion Valsartan can reduce the rate of decline of residual renal function in patients receiving peritoneal dialysis.

关 键 词：缬沙坦 腹膜透析 残存肾功能 

分 类 号：R45[医药卫生—治疗学]